The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG)

Roman Hájek,Jiri Jarkovsky,Walter Bouwmeester,Maarten Treur,Decosta Lucy,Marco Campioni,Michel Delforge,Marc S Raab,Paul Schoen,Zsolt Szabo,Sebastian Gonzalez-Mcquire

doi:10.1182/blood.v128.22.2418.2418

The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG)

Roman Hájek, Jiri Jarkovsky + Show 9 more

https://doi.org/10.1182/blood.v128.22.2418.2418

Copy DOI

Journal: Blood	Publication Date: Dec 2, 2016
Citations: 1

Affiliation: University Hospital Ostrava, Pharmerit (Netherlands), Amgen (United Kingdom), Amgen (Switzerland), Universitair Ziekenhuis Leuven, University Hospital Heidelberg

#Revised- International Staging System #Revised- International Staging System Stage + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG)

Full Text